CommercialSurrounded by controversy, FDA approves Biogen's Alzheimer's drug Aduhelm

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

-

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm, the very first Alzheimer’s medication in the last two decades, which is manufactured by Biogen Pharma.

“Aduhelm is an antibody that attacks the amyloid plaque that has been found to accumulate in the brains of people who have Alzheimer’s disease,” said Dr. Jeffrey Singer to The National Desk’s Jan Jeffcoat. “The only problem is that there’s still a lot of controversy among researchers as to whether or not those plaques are responsible for dementia or are a byproduct of some sort of another inflammatory process that’s causing dementia.”

The three executives of the expert committee of FDA have resigned in protest of Aduhelm’s approval. Dr. Singer said that the FDA has an expedited system for approval of drugs which makes these medications easily accessible by patients who may not have any time to wait.

Dr. singer claims that before 1962, FDA was only obliged to verify a drug’s safety and accurate labeling, not its efficacy.

Latest news

BioNTech Agrees to $205 Million FDA Voucher Purchase for Oncology Pipeline

BioNTech has agreed to pay $205 million to acquire an FDA priority review voucher (PRV) from Scholar Rock, securing...

The Science Behind Bispecific Antibodies and Their Therapeutic Potential

Executive Summary Bispecific antibodies are an increasingly important class of engineered biologic medicines designed to recognize two distinct molecular targets...

Top 10 Emerging Technologies in Microbial Biotechnology

Executive Summary Microbial biotechnology is advancing as new technologies expand the ability to engineer, understand, and utilize microorganisms for industrial,...

Must read

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you